Driver Mutations in Melanoma: Lessons Learned From Bench-to-Bedside Studies

Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM)

(2017) A. Hauschild et al.   JOURNAL OF CLINICAL ONCOLOGY

Multisite Analytic Performance Studies of a Real-Time Polymerase Chain Reaction Assay for the Detection ofBRAFV600E Mutations in Formalin-Fixed, Paraffin-Embedded Tissue Specimens of Malignant Melanoma

(2012) Steven Anderson et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Targeting NRAS in Melanoma

(2012) Fergal C. Kelleher et al.   CANCER JOURNAL

New Strategies in Metastatic Melanoma: Oncogene-Defined Taxonomy Leads to Therapeutic Advances

(2011) K. T. Flaherty et al.   CLINICAL CANCER RESEARCH

KIT as a Therapeutic Target in Metastatic Melanoma

(2011) Richard D. Carvajal   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma

(2011) Satoru Yokoyama et al.   NATURE

A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma

(2011) Corine Bertolotto et al.   NATURE

BRAF targeted therapy changes the treatment paradigm in melanoma

(2011) Antoni Ribas et al.   Nature Reviews Clinical Oncology

Resistance to BRAF Inhibition in Melanomas

(2011) David B. Solit et al.   NEW ENGLAND JOURNAL OF MEDICINE

In vitro studies of dasatinib, its targets and predictors of sensitivity

(2011) Lucia B. Jilaveanu et al.   Pigment Cell & Melanoma Research

Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma

(2011) Bianca Devitt et al.   Pigment Cell & Melanoma Research

A phase 2 trial of dasatinib in advanced melanoma

(2010) Harriet M. Kluger et al.   CANCER

Prognostic factors for survival in melanoma patients with brain metastases

(2010) Michael A. Davies et al.   CANCER

Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma

(2010) J. A. Ellerhorst et al.   CLINICAL CANCER RESEARCH

Somatic alterations in the melanoma genome: A high-resolution array-based comparative genomic hybridization study

(2010) Andreas Gast et al.   GENES CHROMOSOMES & CANCER

Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies

(2010) Luca Sigalotti et al.   Journal of Translational Medicine

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032

(2010) Jill C Rubinstein et al.   Journal of Translational Medicine

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

(2010) Cory M. Johannessen et al.   NATURE

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Mutations inGNA11in Uveal Melanoma

(2010) Catherine D. Van Raamsdonk et al.   NEW ENGLAND JOURNAL OF MEDICINE

Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas

(2010) J. W. Harbour et al.   SCIENCE

Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma

(2009) M. A. Davies et al.   CLINICAL CANCER RESEARCH

Chemotherapy and biologic therapies for melanoma: do they work?

(2009) Lucia B. Jilaveanu et al.   CLINICS IN DERMATOLOGY

Methylation of PTEN as a Prognostic Factor in Malignant Melanoma of the Skin

(2009) Christoph Lahtz et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Activity of dasatinib against L576P KIT mutant melanoma: Molecular, cellular, and clinical correlates

(2009) S. E. Woodman et al.   MOLECULAR CANCER THERAPEUTICS

BrafV600E cooperates with Pten loss to induce metastatic melanoma

(2009) David Dankort et al.   NATURE GENETICS

Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008

(2009) Sanjiv S. Agarwala et al.   Pigment Cell & Melanoma Research

Frequent mutations in the MITF pathway in melanoma

(2009) Julia C. Cronin et al.   Pigment Cell & Melanoma Research

The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma

(2009) SubbaRao V. Madhunapantula et al.   Pigment Cell & Melanoma Research

Combined Targeting of BRAF and CRAF or BRAF and PI3K Effector Pathways Is Required for Efficacy in NRAS Mutant Tumors

(2009) Bijay S. Jaiswal et al.   PLoS One

A novel AKT3 mutation in melanoma tumours and cell lines

(2008) M A Davies et al.   BRITISH JOURNAL OF CANCER

A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel

(2008) K. T. Flaherty et al.   CLINICAL CANCER RESEARCH

Genotypic and Gene Expression Studies in Congenital Melanocytic Nevi: Insight into Initial Steps of Melanotumorigenesis

(2008) Barbara Dessars et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

In melanocytic lesions the fraction of BRAFV600E alleles is associated with sun exposure but unrelated to ERK phosphorylation

(2008) Tiziana Venesio et al.   MODERN PATHOLOGY

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi

(2008) Catherine D. Van Raamsdonk et al.   NATURE